A randomized, double-blind, placebo-controlled phase II study of maintenance therapy with tasquinimod in patients with metastatic castration-resistant prostate cancer responsive to or stabilized during first-line docetaxel chemotherapy

First Line ◽

Double Blind ◽

Double Blind Placebo ◽

Castration Resistant ◽

Docetaxel Chemotherapy

A phase II study of maintenance therapy with temsirolimus (TEM) after response to first-line docetaxel (TAX) chemotherapy in castration-resistant prostate cancer (CRPC).

Journal of Clinical Oncology ◽

10.1200/jco.2010.28.15_suppl.tps246 ◽

2010 ◽

Vol 28 (15_suppl) ◽

pp. TPS246-TPS246 ◽

Cited By ~ 2

Author(s):

U. Emmenegger ◽

S. S. Sridhar ◽

C. M. Booth ◽

R. Kerbel ◽

S. R. Berry ◽

...

Keyword(s):

Prostate Cancer ◽

Maintenance Therapy ◽

Phase Ii ◽

Phase Ii Study ◽

First Line ◽

Orteronel Switch Maintenance Therapy in Metastatic Castration Resistant Prostate Cancer After First-Line Docetaxel: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial (SAKK 08/11)

The Prostate ◽

10.1002/pros.23236 ◽

2016 ◽

Vol 76 (16) ◽

pp. 1519-1527 ◽

Cited By ~ 8

Author(s):

Richard Cathomas ◽

Simon J. Crabb ◽

Michael Mark ◽

Ralph Winterhalder ◽

Christian Rothermundt ◽

...

Keyword(s):

Prostate Cancer ◽

Maintenance Therapy ◽

Controlled Trial ◽

First Line ◽

Double Blind ◽

Double Blind Placebo ◽

Castration Resistant ◽

Switch Maintenance Therapy

2500 Orteronel (Ort) maintenance therapy in patients (pts) with metastatic castration resistant prostate cancer (mCRPC) and non-progressive disease after first-line docetaxel (Doc) therapy: Results of a multicenter randomized double-blind placebo-controlled phase III trial (SAKK 08/11)

European Journal of Cancer ◽

10.1016/s0959-8049(15)30045-9 ◽

2015 ◽

Vol 51 ◽

pp. S473

Author(s):

R. Cathomas ◽

S. Crabb ◽

H. Kenner ◽

M. Mark ◽

C. Rothermundt ◽

...

Keyword(s):

Prostate Cancer ◽

Maintenance Therapy ◽

Progressive Disease ◽

Phase Iii ◽

First Line ◽

Double Blind ◽

Phase Iii Trial ◽

Double Blind Placebo ◽

Faculty Opinions recommendation of Two-year survival follow-up of the randomized, double-blind, placebo-controlled phase II study of radium-223 chloride in patients with castration-resistant prostate cancer and bone metastases.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.718242837.793489809 ◽

2014 ◽

Author(s):

Joan Hester

Keyword(s):

Prostate Cancer ◽

Bone Metastases ◽

Phase Ii ◽

Phase Ii Study ◽

Double Blind ◽

Double Blind Placebo ◽

Castration Resistant ◽

Radium 223

Two-Year Survival Follow-Up of the Randomized, Double-Blind, Placebo-Controlled Phase II Study of Radium-223 Chloride in Patients With Castration-Resistant Prostate Cancer and Bone Metastases

Clinical Genitourinary Cancer ◽

10.1016/j.clgc.2012.07.002 ◽

2013 ◽

Vol 11 (1) ◽

pp. 20-26 ◽

Cited By ~ 79

Author(s):

Sten Nilsson ◽

Lars Franzén ◽

Christopher Parker ◽

Christopher Tyrrell ◽

René Blom ◽

...

Keyword(s):

Prostate Cancer ◽

Bone Metastases ◽

Phase Ii ◽

Phase Ii Study ◽

Double Blind ◽

Double Blind Placebo ◽

Castration Resistant ◽

Radium 223

A phase II study of maintenance therapy with temsirolimus (TEM) after response to first-line docetaxel (TAX) chemotherapy in castration-resistant prostate cancer (CRPC).

Journal of Clinical Oncology ◽

10.1200/jco.2011.29.15_suppl.e15152 ◽

2011 ◽

Vol 29 (15_suppl) ◽

pp. e15152-e15152 ◽

Cited By ~ 1

Author(s):

U. Emmenegger ◽

S. R. Berry ◽

C. M. Booth ◽

S. S. Sridhar ◽

E. Winquist ◽

...

Keyword(s):

Prostate Cancer ◽

Maintenance Therapy ◽

Phase Ii ◽

Phase Ii Study ◽

First Line ◽

Faculty Opinions recommendation of A phase II study of paclitaxel poliglumex in combination with transdermal estradiol for the treatment of metastatic castration-resistant prostate cancer after docetaxel chemotherapy.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.3350956.3039058 ◽

2010 ◽

Author(s):

Yoshihiko Hirao ◽

Kiyohide Fujimoto

Keyword(s):

Prostate Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Castration Resistant ◽

Transdermal Estradiol ◽

Docetaxel Chemotherapy

Phase II randomized, double-blind, placebo-controlled study of tivantinib in men with asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer (mCRPC)

Investigational New Drugs ◽

10.1007/s10637-018-0630-9 ◽

2018 ◽

Vol 36 (5) ◽

pp. 919-926 ◽

Cited By ~ 1

Author(s):

Paul Monk ◽

Glenn Liu ◽

Walter M. Stadler ◽

Susan Geyer ◽

Ying Huang ◽

...

Keyword(s):

Prostate Cancer ◽

Phase Ii ◽

Controlled Study ◽

Double Blind ◽

Double Blind Placebo ◽

An open label phase I/randomised, double-blind phase II study in metastatic castration resistant Prostate Cancer of AZD5363 in combination with Docetaxel and prednisolone chemotherapy (ProCAID)

http://isrctn.org/> ◽

10.1186/isrctn69139368 ◽

2014 ◽

Author(s):

Study Coordinator

Keyword(s):

Prostate Cancer ◽

Phase I ◽

Phase Ii ◽

Phase Ii Study ◽

Open Label ◽

Double Blind ◽

Castration Resistant ◽

Open Label Phase

A phase II study of paclitaxel poliglumex in combination with transdermal estradiol for the treatment of metastatic castration-resistant prostate cancer after docetaxel chemotherapy

Anti-Cancer Drugs ◽

10.1097/cad.0b013e3283355211 ◽

2010 ◽

Vol 21 (4) ◽

pp. 433-438 ◽

Cited By ~ 30

Author(s):

Tomasz M. Beer ◽

Charles Ryan ◽

Joshi Alumkal ◽

Christopher W. Ryan ◽

Janine Sun ◽

...

Keyword(s):

Prostate Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Castration Resistant ◽

Transdermal Estradiol ◽

Docetaxel Chemotherapy